Selective GR Modulators for Chronic Wound Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chronic wounds, such as venous ulcers, pressure ulcers, and diabetic foot ulcers, are difficult to treat due to delayed healing and high recurrence rates, and conventional treatments like glucocorticoids and non-steroidal anti-inflammatory drugs are ineffective or harmful, while existing pharmacological treatments like Recombinant human EGF and Trafermin have limited efficacy.
Innovation Solution
The use of Selective Glucocorticoid Receptor Modulators (SEGRMs) that enhance fibroblast proliferation, increase collagen expression, and inhibit IL-1beta secretion, as demonstrated by compounds like mapracorat and BI-653048, which are tested in vitro for personalized treatment approaches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If topical glucocorticoids are used to treat chronic wounds, then anti-inflammatory effects are achieved, but wound healing is delayed
Solution Approach 1:
The invention segments the glucocorticoid receptor's functions by using selective modulators that can independently activate anti-inflammatory pathways while leaving wound healing pathways unaffected. This allows the treatment to address inflammation without triggering the harmful wound healing delay associated with conventional glucocorticoids.
Solution Approach 2:
The selective glucocorticoid receptor modulators exhibit local quality by demonstrating tissue-specific or pathway-specific effects. They can provide anti-inflammatory benefits in certain cellular contexts while maintaining normal wound healing processes, creating different functional outcomes in different biological pathways.
2Productivity
If conventional treatments like Recombinant human EGF and Trafermin are used, then wound healing is promoted, but therapeutic efficacy is limited
Solution Approach 1:
The invention changes the pharmacological parameter from growth factor supplementation to selective glucocorticoid receptor modulation. This parameter change addresses the fundamental limitation of conventional treatments by targeting the inflammatory component of chronic wound pathology, thereby improving both wound healing rate and therapeutic reliability.
3Object-affected harmful factors
If non-steroidal anti-inflammatory drugs are used, then wound pain is ameliorated, but wound healing is not effectively promoted
Solution Approach 1:
The selective glucocorticoid receptor modulators exhibit multi-functionality by simultaneously addressing multiple aspects of chronic wound pathology: they reduce inflammation, promote wound healing, and can ameliorate pain. This universal action on multiple pathological features distinguishes them from non-steroidal anti-inflammatory drugs that primarily address pain only.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
SEGRMs significantly enhance wound healing by promoting fibroblast activity and collagen production, reducing wound scores, and inhibiting inflammatory cytokines, offering a promising therapeutic option for chronic wounds.
Implementation Method 1
Selective Glucocorticoid Receptor Modulators (SEGRMs) that enhance fibroblast proliferation, increase collagen expression, and inhibit IL-1beta secretion
Data Source
AI summary
The present invention relates to a Selective Glucocorticoid Receptor Modulator (SEGRM), or a pharmaceutically acceptable salt thereof, for use in the treatment of impaired skin wound healing in a subject, an in vitro method for identifying a subject suffering from impaired skin wound healing to be responsive to the treatment with a Selective Glucocorticoid Receptor Modulator (SEGRM), or a pharmaceutically acceptable salt thereof, and kits and kits-of-part related thereto.